UTHR

UTHR

USD

United Therapeutics Corporation Common Stock

$437.330+4.580 (1.058%)

Preço em tempo real

Healthcare
Drug Manufacturers - Specialty & Generic
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$432.750

Máximo

$440.000

Mínimo

$430.020

Volume

0.35M

Fundamentos da empresa

Capitalização de mercado

18.8B

Setor

Drug Manufacturers - Specialty & Generic

País

United States

Estatísticas de negociação

Volume médio

0.79M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $266.98Atual $437.330Máximo $479.5

Notícias relacionadas

BusinessWire

United Therapeutics Corporation to Present at Upcoming Investor Conferences

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming

Ver mais
United Therapeutics Corporation to Present at Upcoming Investor Conferences
BusinessWire

United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease

Ongoing EXPAND Study is the First Clinical Trial to Evaluate Xenotransplantation in End-Stage Renal Disease United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its

Ver mais
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $525

HC Wainwright & Co. analyst Andrew S. Fein maintains United Therapeutics with a Buy and raises the price target from $500 to $525.

Ver mais
HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $525
Analyst Upgrades

RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $587

RBC Capital analyst Lisa Walter maintains United Therapeutics with a Outperform and raises the price target from $569 to $587.

Ver mais
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $587
Analyst Upgrades

Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $423

Wells Fargo analyst Benjamin Burnett maintains United Therapeutics with a Equal-Weight and raises the price target from $414 to $423.

Ver mais
Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $423
BusinessWire

United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key

BusinessWire

United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.